<DOC>
	<DOCNO>NCT01294865</DOCNO>
	<brief_summary>The purpose study investigate plasma level Soluble Urokinase Plasminogen Activator Receptor ( suPAR ) diagnosis treatment sepsis , determine whether diagnostic prognostic value late-onset neonatal sepsis .</brief_summary>
	<brief_title>Soluble Urokinase Plasminogen Activator Receptor ( suPAR ) Late-onset Neonatal Sepsis</brief_title>
	<detailed_description>Infection lead cause neonatal morbidity mortality worldwide . The clinical presentation neonatal infection subtle nonspecific . Microbiologic culture clinical specimen , gold standard diagnosis , low sensitivity available time influence initial therapy . Therefore , reliable rapid vitro test need early diagnosis management infection neonate . suPAR , secrete cell ( neutrophil , lymphocyte , macrophage , endothelial cell ) recently report potential biomarker several infection disease . The level suPAR study newborn infant yet .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<criteria>Infants lateonset neonatal sepsis Infants without parent ' consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Month</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Sepsis</keyword>
	<keyword>late-onset</keyword>
	<keyword>suPAR</keyword>
</DOC>